Medclair (MCLR) Q1 2025 earnings summary

Executive summary

• Achieved 35% year-over-year revenue growth in Q1 2025, reaching SEK 15.6 million, with a gross margin of 71% driven by specific deals.

• EBITDA improved to SEK 5.7 million from SEK 1.3 million, and net income rose to SEK 4.0 million from a loss of SEK 0.2 million in Q1 2024.

• Order intake increased to SEK 22.0 million from SEK 18.0 million, with significant orders from Sweden, Germany, and Denmark.

• Focused on European growth due to geopolitical uncertainty in the US, leveraging a diversified geographic presence.

• Positioned as a leader in sustainable nitrous oxide management for healthcare and recycling sectors.

Financial highlights

• Net sales: SEK 15.6 million (Q1 2024: SEK 11.6 million); gross margin: 71% (Q1 2024: 61%).

• EBITDA: SEK 5.7 million (Q1 2024: SEK 1.3 million); EBIT: SEK 4.0 million (Q1 2024: SEK -0.3 million).

• Net income: SEK 4.0 million (Q1 2024: SEK -0.2 million); EPS: SEK 0.05 (Q1 2024: SEK 0.00).

• Cash flow from operations: SEK 2.4 million (Q1 2024: SEK 0.7 million); cash at period end: SEK 3.6 million.

• Equity ratio: 86% (Q1 2024: 80%); no long-term debt.

Outlook and guidance

• Well positioned for continued growth with strong order intake and established product-market fit.

• Focus remains on Europe and select international markets, with cautious approach to the US.

• Anticipates further growth in healthcare and recycling segments, supported by regulatory and sustainability trends.